Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (…

Breast cancer (BC) is the most frequent carcinoma in women. The cumulative risk for the
disease is 10% up to the age of 80 years. A familial history of BC and ovarian cancer (OC) is a …

A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was
recently implicated in various autoimmune disorders. Tregs are responsible for the …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

… We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10
−8 . The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal …

… All p values were two-sided; p values less than 0·05 were deemed significant. We calculated
95% CIs for logistic regression and Cox regression using the function provided in the SPSS …

… .001) tumors but not in luminal A (P .39) or luminal B/HER2-positive (P … Log-rank P
values were calculated for different pCR definitions and residual disease scores. Hazard …

Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …

… We identified SNPs at 41 new breast cancer susceptibility loci at genome-wide significance
(P < 5 × 10 −8 ). Further analyses suggest that more than 1,000 additional loci are involved …